Spectoliphen 100 222 mg/g Poeder voor gebruik in drinkwater

Authorised

- Lincomycin hydrochloride
- Spectinomycin sulfate tetrahydrate

Product identification

Medicine name:
Spectoliphen 100 222 mg/g Poeder voor gebruik in drinkwater

Active substance:
Lincomycin hydrochloride
Spectinomycin sulfate tetrahydrate

Target species:
Chicken
Pig

Route of administration:
In drinking water use

Product details

Active substance and strength:
Lincomycin hydrochloride
241.90 milligram(s) / 1.00 gram(s)

Spectinomycin sulfate tetrahydrate
671.30 milligram(s) / 1.00 gram(s)

Pharmaceutical form:
Powder for use in drinking water

Withdrawal period by route of administration:
In drinking water use:

- **Chicken**
  - Meat and offal. 4 day

During treatment, animals should not be slaughtered for human consumption.

  - Egg. no withdrawal period

Do not use in animals producing eggs for human consumption

- **Pig**
  - Meat and offal. 3 day

During treatment, animals should not be slaughtered for human consumption.

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01FF52

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Belgium

Available in:
Belgium

Package description:
Spectoliphen 100 Jar with 4.5 kg Powder for use in drinking water

Spectoliphen 100 Jar with 3 kg Powder for use in drinking water
Spectoliphen 100 Jar with 1.5 kg Powder for use in drinking water
Spectoliphen 100 Jar with 150 g Powder for use in drinking water

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
KELA Kempisch Laboratorium Kela Laboratoria

Marketing authorisation date:
9/06/1988

Manufacturing sites for batch release:
KELA Kempisch Laboratorium Kela Laboratoria

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V142721

Date of authorisation status change:
5/08/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.